SCHEMBL2320394

SCHEMBL2320394

Brc1cccc(OC2CCCCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.61
SLC6A4 P31645 1/20 0.61
SLC6A3 Q01959 1/20 0.61
LNPEP Q9UIQ6 1/20 0.47
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAOB P27338 3/20 0.41
PDK2 Q15119 2/20 0.40
KAT6A Q92794 1/20 0.40
HRH1 P35367 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
KCNH2 Q12809 1/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
PLAT P00750 1/20 0.39
KLKB1 P03952 1/20 0.39
PRSS1 P07477 1/20 0.39
NPY1R P25929 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30124975 0.98 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL1337657 0.98 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL29735165 0.94 SLC6A4 (0.63) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL1438129 0.94 SLC6A4 (0.63) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL29711702 0.90 SLC6A4 (0.67) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL1416985 0.90 SLC6A4 (0.67) SLC6A2SLC6A4SLC6A3LNPEPMAOB
Bicarbonate SCHEMBL20548533 0.87 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3LNPEPMEN1
SCHEMBL11663045 0.86 SLC6A4 (0.47) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL19384261 0.82 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3LNPEPMAOB
SCHEMBL19280088 0.82 SLC6A4 (0.58) SLC6A2SLC6A4SLC6A3LNPEPMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
US-8962233-B2 Actinic-ray—or radiation-sensitive resin composition and method of forming pattern using the composition FUJIFILM CORPORATION (JP) 2015-02-24 US disclosed
US-20110189609-A1 ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE COMPOSITION FUJIFILM CORPORATION (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189609-A1 ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE COMPOSITION ARSA, RER1, TERB1 SLC6A2 3102/4885SLC6A4 2993/4885SLC6A3 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.